Oncolytics Biotech Inc (ONCY) company profile
Close on Nov 17, 2026Market cap $48.77MP/E –Yield –
About Oncolytics Biotech
Pharmaceutical Preparations, SIC 2834
Oncolytics Biotech is a clinical-stage biopharmaceutical enterprise focused on developing pelareorep, an intravenously administered immunotherapeutic candidate. Pelareorep is a proprietary isolate of reovirus designed to replicate selectively inside RAS-mutated tumor cells, stimulate innate and adaptive immune defenses, and transform the immunosuppressive microenvironment of solid tumors. The firm prioritizes platform development for gastrointestinal malignancies—including pancreatic ductal adenocarcinoma, anal canal carcinoma, and metastatic colorectal cancer—alongside clinical evaluations in breast cancer. These investigational programs aim to improve clinical responses when paired with chemotherapy or checkpoint inhibitors. Target beneficiaries comprise oncology patients who have exhausted or derived minimal benefit from current standard cancer therapies.
The enterprise conducts its research programs internationally across multiple jurisdictions, utilizing external study sites and clinical collaborations throughout North America. It manages a portfolio of 137 patents spanning the United States, Canada, and other foreign regions. Manufacturing operations rely principally on a single toll manufacturer located within the United States to supply clinical-grade active ingredients and formulated drug products. The provided text contains no details disclosing the company's corporate headquarters location.
Summary of the business section of Oncolytics Biotech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Oncolytics Biotech Inc
- Founded
- 1998
- Headquarters
- San Diego, CA
- Address
- Suite 325, 4350 Executive Drive 92121
- Phone
- (403) 670-7377
- Website
- www.oncolyticsbiotech.com
- Employees
- 29, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Calgary, Canada
Stock & identifiers
- Ticker
- ONCY
- Exchange
- Nasdaq
- IPO date
- Oct 5, 2001
- Shares outstanding
- 128M, Aug 10, 2026
- Public float
- $72.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-9.5 reverse, Mar 15, 2019; 1-for-9.5 reverse, May 25, 2018
- SEC CIK
- 1129928
- CUSIP
- 68237V103
- ISIN
- US68237V1035
- FIGI
- BBG000DVS826
- Share class FIGI
- BBG001SDGSF3
- EIN
- 98-0541667
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jared Kelly | Chief Executive Officer, Director | 114,050 |
| John Bearden McAdory | Chief Operating Officer | – |
| Kirk Look | Chief Financial Officer | 287,515 |
| Allison Hagerman | Chief Technology Officer | 115,059 |
| Thomas Charles Heineman | Chief Medical Officer | 282,818 |
| Andrew Aromando | Chief Business Officer | 55,100 |
| Deborah Margaret Brown | Director | 109,851 |
| Stephen C. Glover | Director | – |
| Angela Holtham | Director | 183,639 |
| Jonathan Rigby | Director | 42,728 |
| Wayne Pisano | Director | 492,414 |
| James T. Parsons | Director | 41,849 |
| Bernd R. Seizinger | Director | 566,991 |
| Patricia S. Andrews | Director | 78,128 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Kelly | $2.11M | $6.04M | $1.16M | $65 | – |
| FY2025 Pisano | $433.14K | $464.74K | $1.16M | $65 | – |
| FY2024 Coffey | $739.61K | $406.97K | $731.48K | $68 | – |
| FY2024 Pisano | $233.78K | $214.16K | $731.48K | $68 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Jared Kelly Chief Executive Officer | $318.09K | – | $1.78M | – | $9.58K | $2.11M | – |
| Wayne Pisano Former Interim CEO | $110.00K | $124.42K | $108.72K | $50.00K | $40.00K | $433.14K | +85% |
| Thomas C. Heineman Chief Medical Officer | $550.97K | – | $521.87K | $110.50K | $14.00K | $1.20M | +51% |
| Kirk Look Chief Financial Officer | $460.98K | – | $547.05K | $90.50K | $23.71K | $1.12M | +67% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 29 total and full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 24, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 8, 2026 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Oct 20, 2025 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| May 31, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 24, 2015 | Delisting | Notice of delisting from exchange (Form 25) |
See a number that looks wrong?